港股異動 | 復星醫藥(2196.HK)跌超5% 遭投行下調目標價及評級
格隆匯11月3日丨復星醫藥(2196.HK)股價弱勢震盪,現報22.55港元,跌幅5.5%,總市值602億港元。公司此前披露,控股子公司Fosun Pharma Pte擬2.17億新幣受讓OncoCare合計60%股權。由於本次交易交割先決條件涉及的環節較多,未能於各方約定的期限內(2022年10月30日前)全部達成,因此各方同意本次交易依約終止。另外,富瑞發表報吿指,由於復必泰疫苗在內地批准無期,該行將復必泰疫苗自復星醫藥估值中剔除,將公司目標價由90港元大幅下調至26港元,並將其評級降至持有。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.